Ozempic and pregnancy: Landmark study of 750,000 reveals a surprising twist
A large-scale Danish registry study analyzing more than 750,000 pregnancies has offered new insights into the potential risks of exposure to GLP-1 receptor agonists, including Ozempic (semaglutide), Wegovy and liraglutide, around conception and early pregnancy.
According to ScienceDaily, the research found no increased risk of preterm birth associated with early exposure to these medications when prescribed for weight management. However, women taking GLP-1 drugs for pre-existing type 2 diabetes showed a higher association with premature delivery.
Diabetes or........
